Insys Therapeutics weakness a buying opportunity, says JMP Securities JMP Securities said Insys Therapeutics (INSY) is weak on concerns that Subsys may be added to Express Scripts' (ESRX) exclusion list in 2015. The analyst does not know if it will or not be added but said the potential impact would not be material to sales or growth because the product is not included in any PBM preferred formula positions and has prior authorization requirements. The analyst would use weakness as a buying opportunity and reiterates its Outperform rating and $65 price target.
Insys Therapeutics receives FDA orphan drug designation to CBD candidate Insys Therapeutics announced that the FDA has granted orphan drug designation, or ODD, to its pharmaceutical cannabidiol, or CBD, candidate for the treatment of pediatric schizophrenia. This marks the fifth ODD for the company's CBD program.